Evidence map›Paper›PMID 42252303›Full record

ArticleActa pharmacologica Sinica2026

Metabolic checkpoint blockade of IL4I1 by ZY-MY-111 reactivates CD8

Ju-Fei Li, Hao Wang, Ling Kang, Cheng-Cheng Xu, Yuan-Chun Liu, Zi-Xuan Li, Shao-Hao Lin, Ming-Zhi Wang, Xiao-Min Xu, Pei-Pei Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ju-Fei Li *School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Hao Wang *Drug Discovery & Development Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Ling Kang *School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Cheng-Cheng Xu *Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China.
Yuan-Chun LiuCollege of Life Science and Technology, Xinjiang University, Xinjiang, 830046, China.
Zi-Xuan LiDrug Discovery & Development Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Shao-Hao LinSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Ming-Zhi WangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Xiao-Min XuZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China.
Pei-Pei WangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Wan-Chao YinZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China. wcyin@simm.ac.cn.
Yu-Bo ZhouZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China. ybzhou@simm.ac.cn.
Yu ZhouDrug Discovery & Development Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. zhouyu@simm.ac.cn.
Jia LiSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. jli@simm.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic hijacking of tryptophan (Trp) via the IL4I1-AHR axis is a pivotal immune evasion mechanism in cancers, yet therapeutic strategies to disrupt this pathway remain unexplored. Here, we report the identification of ZY-MY-111, a selective small-molecule inhibitor of interleukin-4-induced-1 (IL4I1), through an in-house compound library screening and structural optimization. ZY-MY-111 exhibits potency (IC

Indexed as

Antineoplastic AgentsCD8-Positive T-LymphocytesAnimalsCell Line, TumorCell ProliferationColonic NeoplasmsFemaleHumansL-Amino Acid OxidaseMiceMice, Inbred BALB CMice, Inbred C57BLTumor MicroenvironmentAntineoplastic AgentsIL4I1 protein, humanIl4i1 protein, mouseL-Amino Acid Oxidasearyl hydrocarbon receptor (AHR)CD8+ T cellsimmunotherapyinterleukin-4-induced-1 (IL4I1)tryptophan metabolismtumor immune microenvironment

Identifiers

PMID42252303
PMCPMC13486831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.